研報掘金丨開源證券:山東藥玻核心壁壘穩固,護城河深厚,首予“買入”評級
開源證券研報指出,山東藥玻(600529.SH)是國內藥玻行業龍頭,核心壁壘穩固,護城河深厚。公司定增建設40億支一級耐水藥用玻璃瓶項目,項目產品以中硼硅玻璃模製瓶爲主,截至2024H1公司產能已投放過半且項目仍在持續建設中。隨着公司中硼硅模製瓶逐步放量,公司收入、利潤有望迎來較好增長。此外,關聯審評審批制度推行加速藥用包材行業集中度提升,公司作爲行業龍頭預計受益。首次覆蓋,給予“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.